Stroke scales (NIHSS), ICH scoring, Glasgow Coma Scale, and neurologic disability assessments.
Predicts volume of intracranial hemorrhage from CT measurements using a simplified ellipsoid formula. Widely used bedside method for rapid ICH volume estimation.
Estimates stroke risk after a transient ischemic attack (TIA), based on patient risk factors
Measures involuntary movements of tardive dyskinesia (TD) in patients receiving neuroleptic medications
Track functional decline in amyotrophic lateral sclerosis (12 items).
Assigns phenotype in patients with ischemic stroke of uncertain causes by evaluating five main etiologic categories: Atherothrombosis, Small-vessel disease, Cardiac pathology, Other causes, and Dissection. Provides a comprehensive classification system that captures overlap between multiple underlying stroke mechanisms.
Quantifies early ischemic changes in MCA territory on non-contrast CT to predict stroke outcome and guide treatment decisions
Predicts 90-day poor outcome (mRS >2) in patients with acute ischemic stroke. The score combines age, NIHSS, timing, visual defects, glucose levels, and consciousness to stratify prognosis.
Predicts risk of delirium during hospitalization using age, cognitive function, orientation, and illness severity
Assesses ability to swallow without aspiration after stroke. This screening tool helps identify stroke patients at risk for dysphagia and aspiration, allowing safe initiation of oral intake while preventing aspiration complications.
The Canadian TIA Score identifies risk of stroke, carotid endarterectomy, or carotid artery stenting within 7 days in patients who experienced TIA symptoms. It incorporates 13 predictive variables from history, physical examination, and testing routinely performed in the emergency department.
Calculates cerebral perfusion pressure (CPP), the net pressure gradient that drives oxygen delivery to cerebral tissue. Critical parameter in neurocritical care for monitoring patients with traumatic brain injury, intracranial hypertension, and other neurological conditions.
Stages dementia, including Alzheimer's disease, in elderly patients. The CDR assesses cognitive and functional performance across six domains to provide both a global CDR score (0-3) and a sum of boxes score (0-18).
CSF protein corrected for blood contamination in traumatic tap.
CSF WBC corrected for blood contamination in traumatic tap.
Phenytoin corrected for hypoalbuminemia and renal failure.
Assesses MS disease progression based on patient's ambulatory ability
25-item self-assessment of dizziness-related handicap.
10-item screening tool for neuropathic pain.
Predicts 3-month outcome (functional independence vs dependency) in ischemic stroke patients treated with tissue plasminogen activator (tPA). Helps identify patients who may benefit from additional therapeutic interventions.
Describes severity of disability in MS patients based on functional systems assessment and ambulatory ability. The most widely used disability scale for multiple sclerosis.
Diagnostic criteria for identifying embolic stroke of undetermined source after comprehensive evaluation excluding other specific stroke etiologies.
Assesses risk of vasospasm in SAH based on amount and distribution of blood on CT
Rapid clinical test for delirium detection in elderly patients. Includes cognitive test items, also suitable as a quick test for cognitive impairment.
Grades severity of coma; may be more accurate than Glasgow Coma Scale. Evaluates consciousness level through four components: eye response, motor response, brainstem reflexes, and respiration pattern.
Identifies patients with intracerebral hemorrhage (ICH) who will achieve functional independence at 90 days and aids in clinical decision-making and goals of care discussions.
6-level walking ability classification.
The GCS-Pupils Score (GCS-P) combines the Glasgow Coma Scale with pupillary reactivity assessment to provide enhanced prognostic accuracy in traumatic brain injury patients. This extended index offers improved prediction of 6-month mortality and unfavorable outcomes, particularly in patients with severe brain injury where standard GCS may be limited.
Clinical scale used to assess level of consciousness and neurological function in patients with acute brain injury. Evaluates three components: eye opening response (1-4), verbal response (1-5), and motor response (1-6) for a total score ranging from 3-15
Predicts hemorrhage risk after tPA administration in acute ischemic stroke patients. Helps determine risk/benefit of tPA in borderline cases and identify patients needing closest monitoring.
Estimates seizure risk in acutely ill patients undergoing continuous EEG (cEEG). Combines clinical factors and EEG findings to guide appropriate monitoring duration.
Helps differentiate between peripheral and central causes of acute vestibular syndrome, primarily to identify strokes affecting the posterior circulation. Uses three bedside examination components: Head Impulse test, Nystagmus evaluation, and Test of Skew.
Classifies severity of aneurysmal subarachnoid hemorrhage based on clinical presentation to predict mortality and guide surgical risk assessment. Uses neurological symptoms and level of consciousness to assign grades I-V.
Grades clinical severity of subarachnoid hemorrhage; predicts surgical risk and outcome.
Estimates 30-day mortality risk in patients with spontaneous intracerebral hemorrhage based on clinical and radiographic findings at presentation. The ICH Score was developed to provide a simple, reliable clinical grading scale analogous to those used for traumatic brain injury, subarachnoid hemorrhage, and ischemic stroke. This validated prognostic tool uses five independent risk factors identified through multivariate analysis: Glasgow Coma Scale score, age ≥80 years, infratentorial hemorrhage location, ICH volume ≥30 cm³, and presence of intraventricular hemorrhage. The score ranges from 0-6 points with excellent discrimination for 30-day mortality prediction. ICH Score standardizes clinical assessment, facilitates treatment protocol development, improves research study design, and enables evidence-based prognostic discussions with patients and families. The tool is particularly valuable for early risk stratification and clinical decision-making in acute intracerebral hemorrhage management.
Predicts 6-month mortality and unfavorable outcomes after moderate to severe traumatic brain injury (TBI). The International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) score uses three progressive models (Core, Extended, Lab) to provide evidence-based prognosis in patients with GCS ≤12. Developed from a database of 8,509 acute TBI patients from 8 randomized controlled trials and 3 observational studies. This validated prognostic tool assists clinicians in counseling families, making treatment decisions, and planning care for severe TBI patients. The Core model uses only clinical variables (age, motor score, pupillary reactivity), while Extended adds CT findings and Lab incorporates laboratory values for enhanced accuracy.
Diagnoses Alzheimer's disease (AD) using revised research diagnostic criteria that integrate clinical phenotypes with pathophysiological biomarkers. The IWG-2 criteria represent a major advancement over previous diagnostic approaches by requiring both an appropriate clinical AD phenotype (typical or atypical) and pathophysiological biomarker evidence of Alzheimer pathology. This framework covers the full disease spectrum from asymptomatic at-risk individuals to typical and atypical AD presentations. The IWG-2 criteria distinguish between pathophysiological markers (CSF Aβ1-42, T-tau, P-tau, amyloid PET) used for diagnosis and topographical markers (volumetric MRI, FDG-PET) used for progression monitoring. This diagnostic tool enables earlier and more accurate identification of AD across the disease continuum, facilitating appropriate treatment planning and research enrollment.
Grades vestibular schwannoma extension into the cerebellopontine angle.
Leeds Assessment of Neuropathic Symptoms and Signs; >=12 suggests neuropathic pain.
Stratifies stroke severity in the field to identify patients with large vessel occlusion
Classifies traumatic brain injury on initial head CT into 6 prognostic categories (Marshall et al., 1991). Mass lesions take precedence over diffuse-injury grading; evacuated vs non-evacuated status must be specified.
Diagnoses multiple sclerosis using clinical attacks, lesion characteristics, and MRI findings. The 2017 revision introduces key changes including the use of CSF oligoclonal bands to substitute for dissemination in time, acceptance of symptomatic lesions in brainstem/spinal cord, and inclusion of cortical lesions for dissemination in space criteria.
Assesses disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms. This patient-reported scale measures symptom impact on bulbar, respiratory, gross motor, and ocular functions.
Quantifies headache-related disability over a 3-month period to guide treatment decisions
Screens for mild cognitive impairment with assessment of multiple cognitive domains including attention, executive function, memory, language, visuospatial skills, abstraction, and orientation.
Measures the impact that fatigue has on patient's daily life across physical, cognitive, and psychosocial domains
States severity of aneurysmal subarachnoid hemorrhage based on amount and type of blood on CT with associated risk of vasospasm
Grades severity of symptoms in Parkinson's disease with intermediate stages for better disease progression tracking
Shortened, validated version of NIH Stroke Scale for quantifying stroke severity with improved interrater reliability
Measures the degree of disability or dependence in daily activities of people who have suffered a stroke or other causes of neurological disability
9-question yes/no survey that provides simple and reliable determination of the modified Rankin Scale score in neurosurgical and neurological patients
Predicts short-term mortality in acute stroke by adding NIHSS score to the original SOAR criteria, improving prognostic accuracy while maintaining clinical practicality.
Multiple Sclerosis Functional Composite (Fischer 1999): z-scores of timed 25-foot walk, 9-hole peg test, and PASAT-3 against the reference population; MSFC = mean of the three z-scores. Positive = better than reference average.
Determines effectiveness of current migraine treatment plan to guide treatment optimization decisions
Quantifies severity of neuropathic pain using 10 specific pain quality dimensions. Only for patients already diagnosed with neuropathic pain.
Offers criteria for which patients are unlikely to require imaging after head trauma. Use ONLY in patients with head injury and loss of consciousness who are neurologically normal (GCS 15).
Quantifies stroke severity based on weighted evaluation findings. The NIHSS is a 15-item neurological examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss.
Quantifies the severity of functional disability in peripheral neuropathy by assessing upper and lower extremity functional activities. This validated scale is widely used to track disease progression and treatment response in various neuropathic conditions, particularly immune-mediated polyneuropathies.
painDETECT Questionnaire (Freynhagen 2006) for neuropathic pain components: 7 sensory items (0-5) + pain course pattern (-1/0/+1) + radiating pain (+2/0); total -1 to 38. ≤12 neuropathic unlikely, 13-18 ambiguous, ≥19 neuropathic likely.
Phenytoin correction for hypoalbuminemia (Sheiner-Tozer): corrected = measured / (0.2 × albumin + 0.1); in renal failure: measured / (0.1 × albumin + 0.1). Albumin in g/dL. Use when albumin <3.5 g/dL to estimate free phenytoin exposure.
13-item objective severity scale for myasthenia gravis, each item 0-3; total 0-39. Tracks treatment response.
CT prognostic score in TBI: sum of 4 components + 1; 1-6 (higher = worse).
Identifies vertigo patients at higher risk for serious central diagnosis including stroke, TIA, vertebral artery dissection, or brain tumor in the emergency department setting.
Evaluates eligibility and contraindications for thrombolytic therapy with IV tPA in acute ischemic stroke patients. Reviews absolute and relative contraindications based on AHA/ASA guidelines.
Quantifies disability after stroke; also validated in Parkinson's disease. Assesses static sitting balance, dynamic sitting balance, and coordination through 17 specific motor tasks.
Unified Parkinson's Disease Rating Scale (UPDRS) total from prescored part subtotals. Part I mentation/behavior/mood (0-16), Part II activities of daily living (0-52), Part III motor examination (0-108), Part IV complications of therapy (0-23). Total 0-199; higher scores indicate greater disease severity.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.